SELLAS Life Sciences (SLS) Cash from Investing Activities Growth (1y) (2011 - 2017)
SELLAS Life Sciences (SLS) Cash from Investing Activities Growth (1y) (2011 - 2017) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.89 Bn | 1.78 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 15,489.87% |
| Jun 30, 2017 | -100.67% |
| Mar 31, 2017 | 98.30% |
| Dec 31, 2016 | -100.74% |
| Jun 30, 2016 | 6,662.50% |
| Mar 31, 2016 | -5,766.67% |
| Dec 31, 2015 | 262.30% |
| Sep 30, 2015 | 91.93% |
| Jun 30, 2015 | 94.87% |
| Mar 31, 2015 | 99.11% |
| Dec 31, 2014 | 205.10% |
| Sep 30, 2014 | -527.08% |
| Jun 30, 2014 | -338.17% |
| Mar 31, 2014 | 79.86% |
| Dec 31, 2011 | -101.70% |